• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
[Chinese Expert Consensus on the Clinical Practice of Non-small Cell Lung Cancer 
Fusion Gene Detection Based on RNA-based NGS].《基于RNA的二代测序技术检测非小细胞肺癌融合基因的临床实践中国专家共识》
Zhongguo Fei Ai Za Zhi. 2023 Nov 20;26(11):801-812. doi: 10.3779/j.issn.1009-3419.2023.102.43. Epub 2023 Nov 21.
2
Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.将下一代测序(NGS)纳入亚洲非小细胞肺癌(NSCLC)人群的实用性:可操作改变的增量收益和成本效益分析。
Lung Cancer. 2020 Jan;139:207-215. doi: 10.1016/j.lungcan.2019.11.022. Epub 2019 Nov 26.
3
Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer.基于扩增子的游离血浆 DNA 下一代测序检测晚期非小细胞肺癌中的驱动和耐药突变。
Ann Oncol. 2018 Apr 1;29(4):1049-1055. doi: 10.1093/annonc/mdy005.
4
Portuguese Consensus Recommendations for Next-Generation Sequencing of Lung Cancer, Rare Tumors, and Cancers of Unknown Primary Origin in Clinical Practice.葡萄牙临床实践中肺癌、罕见肿瘤及原发灶不明癌症的下一代测序共识建议。
Acta Med Port. 2022 Sep 1;35(9):677-690. doi: 10.20344/amp.17680. Epub 2022 Jul 11.
5
Molecular characteristics and clinical outcomes of complex ALK rearrangements identified by next-generation sequencing in non-small cell lung cancers.下一代测序鉴定非小细胞肺癌中复杂 ALK 重排的分子特征和临床结局。
J Transl Med. 2021 Jul 16;19(1):308. doi: 10.1186/s12967-021-02982-4.
6
Reliability analysis of exonic-breakpoint fusions identified by DNA sequencing for predicting the efficacy of targeted therapy in non-small cell lung cancer.基于 DNA 测序的外显子断点融合的可靠性分析,预测非小细胞肺癌靶向治疗的疗效。
BMC Med. 2022 May 10;20(1):160. doi: 10.1186/s12916-022-02362-9.
7
Optimising fusion detection through sequential DNA and RNA molecular profiling of non-small cell lung cancer.通过对非小细胞肺癌的 DNA 和 RNA 分子连续分析进行融合检测的优化。
Lung Cancer. 2021 Nov;161:55-59. doi: 10.1016/j.lungcan.2021.08.008. Epub 2021 Aug 25.
8
Targeted RNA sequencing for upfront analysis of actionable driver alterations in non-small cell lung cancer.用于非小细胞肺癌中可操作驱动改变的前期分析的靶向RNA测序。
Lung Cancer. 2022 Apr;166:242-249. doi: 10.1016/j.lungcan.2022.02.013. Epub 2022 Mar 1.
9
Detecting ALK Rearrangement with RT-PCR: A Reliable Approach Compared with Next-Generation Sequencing in Patients with NSCLC.使用 RT-PCR 检测 ALK 重排:与 NSCLC 患者的下一代测序相比,这是一种可靠的方法。
Mol Diagn Ther. 2021 Jul;25(4):487-494. doi: 10.1007/s40291-021-00532-8. Epub 2021 Jun 16.
10
Detection of multiple types of cancer driver mutations using targeted RNA sequencing in non-small cell lung cancer.使用靶向 RNA 测序在非小细胞肺癌中检测多种类型的癌症驱动突变。
Cancer. 2023 Aug 1;129(15):2422-2430. doi: 10.1002/cncr.34804. Epub 2023 Apr 25.

引用本文的文献

1
Exploring psychological distress among lung cancer patients through the stress system model.通过应激系统模型探索肺癌患者的心理困扰。
Sci Rep. 2025 Jul 26;15(1):27253. doi: 10.1038/s41598-025-09847-6.
2
An accurate DNA and RNA based targeted sequencing assay for clinical detection of gene fusions in solid tumors.一种基于DNA和RNA的精确靶向测序检测方法,用于实体瘤中基因融合的临床检测。
Sci Rep. 2025 Feb 28;15(1):7223. doi: 10.1038/s41598-025-91640-6.
3
Establishment of potential reference measurement procedure and reference materials for EML4-ALK fusion variants measurement.建立 EML4-ALK 融合变体测量的潜在参考测量程序和参考物质。
Sci Rep. 2024 Oct 19;14(1):24543. doi: 10.1038/s41598-024-76618-0.
4
[A Case of EML4-ALK Fusion V1 Subtype Lung Adenocarcinoma 
Detected by RNA-based NGS].[一例通过基于RNA的二代测序检测到的EML4-ALK融合V1亚型肺腺癌病例]
Zhongguo Fei Ai Za Zhi. 2024 Jun 20;27(6):480-484. doi: 10.3779/j.issn.1009-3419.2024.102.23.

本文引用的文献

1
Pan-TRK immunohistochemistry as screening tool for NTRK fusions: A diagnostic workflow for the identification of positive patients in clinical practice.泛 TRK 免疫组化作为 NTRK 融合的筛查工具:一种用于在临床实践中鉴定阳性患者的诊断工作流程。
Cancer Biomark. 2023;38(3):301-309. doi: 10.3233/CBM-220357.
2
Next Generation Sequencing Analysis and its Benefit for Targeted Therapy of Lung Adenocarcinoma.下一代测序分析及其对肺腺癌靶向治疗的益处。
Cancer Genomics Proteomics. 2023 Jul-Aug;20(4):404-411. doi: 10.21873/cgp.20392.
3
RNA Extraction Method Impacts Quality Metrics and Sequencing Results in Formalin-Fixed, Paraffin-Embedded Tissue Samples.RNA提取方法对福尔马林固定石蜡包埋组织样本的质量指标和测序结果有影响。
Lab Invest. 2023 Feb;103(2):100027. doi: 10.1016/j.labinv.2022.100027. Epub 2023 Jan 10.
4
Gene Expression Profiling of FFPE Samples: A Titration Test.FFPE 样本的基因表达谱分析:滴定试验。
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221129710. doi: 10.1177/15330338221129710.
5
[Chinese expert consensus on clinical practice of MET detection in non-small cell lung cancer].《非小细胞肺癌MET检测临床实践中国专家共识》
Zhonghua Bing Li Xue Za Zhi. 2022 Nov 8;51(11):1094-1103. doi: 10.3760/cma.j.cn112151-20220606-00491.
6
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer.Telisotuzumab Vedotin 联合厄洛替尼治疗 c-Met 蛋白表达的非小细胞肺癌的 Ib 期研究。
J Clin Oncol. 2023 Feb 10;41(5):1105-1115. doi: 10.1200/JCO.22.00739. Epub 2022 Oct 26.
7
Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib.肺腺癌伴复杂 EML4-ALK 融合和 BRAF V600E 共突变对艾乐替尼有反应。
Medicine (Baltimore). 2022 Oct 7;101(40):e30913. doi: 10.1097/MD.0000000000030913.
8
Durable response to crizotinib in an advanced lung adenocarcinoma patient harboring rare fusion: a case report.一例罕见融合基因的晚期肺腺癌患者对克唑替尼的持久反应:病例报告
Transl Cancer Res. 2022 Aug;11(8):2931-2935. doi: 10.21037/tcr-22-141.
9
Rapid response to monotherapy with MEK inhibitor trametinib for a lung adenocarcinoma patient harboring primary fusion: A case report and literature review.一名携带原发性 融合的肺腺癌患者对MEK抑制剂曲美替尼单药治疗的快速反应:病例报告及文献综述
Front Oncol. 2022 Aug 19;12:945620. doi: 10.3389/fonc.2022.945620. eCollection 2022.
10
Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequences.基于 RNA 的 NGS 检测 ALK 融合变体与接受 ALK-TKI 序贯治疗的 NSCLC 患者的临床结局相关性。
Eur J Cancer. 2022 Oct;174:200-211. doi: 10.1016/j.ejca.2022.07.026. Epub 2022 Aug 28.

《基于RNA的二代测序技术检测非小细胞肺癌融合基因的临床实践中国专家共识》

[Chinese Expert Consensus on the Clinical Practice of Non-small Cell Lung Cancer 
Fusion Gene Detection Based on RNA-based NGS].

出版信息

Zhongguo Fei Ai Za Zhi. 2023 Nov 20;26(11):801-812. doi: 10.3779/j.issn.1009-3419.2023.102.43. Epub 2023 Nov 21.

DOI:10.3779/j.issn.1009-3419.2023.102.43
PMID:37985137
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10714047/
Abstract

RNA-based next-generation sequencing (NGS) has been recommended as a method for detecting fusion genes in non-small cell lung cancer (NSCLC) according to clinical practice guidelines and expert consensus. The primary targetable alterations in NSCLC consist of gene mutations and fusions, making the detection of gene mutations and fusions indispensable for assessing the feasibility of targeted therapies. Currently, the integration of DNA-based NGS and RNA-based NGS allows for simultaneous detection of gene mutations and fusions and has been partially implemented in clinical practice. However, standardized guidelines and criteria for the significance, application scenarios, and quality control of RNA-based NGS in fusion gene detection are still lacking in China. This consensus aims to provide further clarity on the practical significance, application scenarios, and quality control measures of RNA-based NGS in fusion gene detection. Additionally, it offers guiding recommendations to facilitate the clinical implementation of RNA-based NGS in the diagnosis and treatment of NSCLC, ultimately maximizing the benefits for patients from fusion gene detection.
.

摘要

根据临床实践指南和专家共识,基于RNA的下一代测序(NGS)已被推荐作为检测非小细胞肺癌(NSCLC)融合基因的一种方法。NSCLC中主要的可靶向改变包括基因突变和融合,这使得检测基因突变和融合对于评估靶向治疗的可行性不可或缺。目前,基于DNA的NGS和基于RNA的NGS相结合可同时检测基因突变和融合,并且已在临床实践中部分实施。然而,我国在基于RNA的NGS用于融合基因检测的意义、应用场景和质量控制方面仍缺乏标准化的指南和标准。本共识旨在进一步明确基于RNA的NGS在融合基因检测中的实际意义、应用场景和质量控制措施。此外,它还提供指导性建议,以促进基于RNA的NGS在NSCLC诊断和治疗中的临床应用,最终使患者从融合基因检测中获得最大益处。